Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770468 · ClinicalTrials.gov registry record
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
A clinical trial, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- Completed
- Registry status
- 599
- Enrollment target
NCT03770468: Completed study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
NCT03770468 is a clinical trial that has completed, run by European Organisation for Research and Treatment of Cancer - EORTC. The registered enrollment target is 599 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03770468 has completed, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- COMPLETED
- Registry status
- 599 participants
- Enrollment target
Study Summary
This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years. The different research focusses are: * Identification of clinical parameters and patient characteristics / host-related factors in long-term survivors (Focus 1) * Identification of molecular tumor characteristics in long-term survivors (Focus 2) * Assessment of therapy-related parameters, including neuro-toxicity (Focus 3) * Immunological studies (Focus 4)
Interventions
- PROCEDURE Blood drawl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2015-07-05 |
| Est. Completion | 2023-08-18 |
What the finished NCT03770468 record still lists
NCT03770468 is an observational study that tracks outcomes without assigning an intervention. The registered 599 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Blood drawl is the first listed.
NCT03770468 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03770468 about?
NCT03770468 is a clinical study titled "Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma". This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years. The different research focusses are: * Identification of clinical parameters and pati...
What is the current status of trial NCT03770468?
This trial is currently completed. The enrollment target is 599 participants. The study started on 2015-07-05. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT03770468?
The interventions under investigation include: Blood drawl (PROCEDURE).
Who is sponsoring clinical trial NCT03770468?
This trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI